Zhejiang Tianyu Pharmaceutical Co Ltd Market Cap ($1.03 Billion)
Market Cap & Net Worth: Zhejiang Tianyu Pharmaceutical Co Ltd (300702)
Zhejiang Tianyu Pharmaceutical Co Ltd market cap. Zhejiang Tianyu Pharmaceutical Co Ltd (SHE:300702) has a market capitalization of $1.03 Billion (CN¥7.03 Billion) as of November 3, 2026. Listed on the SHE stock exchange, this China-based company holds position #8476 globally and #1924 in its home market, demonstrating a 0.65% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Zhejiang Tianyu Pharmaceutical Co Ltd's stock price CN¥20.21 by its total outstanding shares 347977159 (347.98 Million). Also see Zhejiang Tianyu Pharmaceutical Co Ltd cash flow conversion for how efficiently the company converts equity into cash flow.
Zhejiang Tianyu Pharmaceutical Co Ltd Market Cap History (2017–2026)
Zhejiang Tianyu Pharmaceutical Co Ltd market cap history from 2017 to 2026. Data shows growth from $760.42 Million to $1.03 Billion (6.15% CAGR). Check today's stock price for Zhejiang Tianyu Pharmaceutical Co Ltd for real-time trading data and today's change.
Zhejiang Tianyu Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Zhejiang Tianyu Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore 300702 net assets growth trend to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.39x
Zhejiang Tianyu Pharmaceutical Co Ltd's market cap is 0.39 times its annual revenue
Latest Price to Earnings (P/E) Ratio
8.60x
Zhejiang Tianyu Pharmaceutical Co Ltd's market cap is 8.60 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $760.42 Million | $1.19 Billion | $100.18 Million | 0.64x | 7.59x |
| 2018 | $605.10 Million | $1.47 Billion | $163.66 Million | 0.41x | 3.70x |
| 2019 | $1.39 Billion | $2.11 Billion | $585.73 Million | 0.66x | 2.38x |
| 2020 | $2.61 Billion | $2.59 Billion | $667.06 Million | 1.01x | 3.92x |
| 2021 | $2.45 Billion | $2.55 Billion | $204.68 Million | 0.96x | 11.96x |
| 2022 | $1.30 Billion | $2.67 Billion | -$118.87 Million | 0.49x | N/A |
| 2023 | $1.10 Billion | $2.53 Billion | $27.36 Million | 0.44x | 40.30x |
| 2024 | $848.33 Million | $2.63 Billion | $55.94 Million | 0.32x | 15.17x |
| 2025 | $1.20 Billion | $3.06 Billion | $139.71 Million | 0.39x | 8.60x |
Competitor Companies of 300702 by Market Capitalization
Companies near Zhejiang Tianyu Pharmaceutical Co Ltd in the global market cap rankings as of November 3, 2026. Also see Zhejiang Tianyu Pharmaceutical Co Ltd (300702) total assets for a full breakdown of the balance sheet.
Key companies related to Zhejiang Tianyu Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #516 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #536 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #591 globally with a market cap of $45.45 Billion USD ( CN¥310.59 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #618 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #516 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #536 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.55 |
| #591 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.45 Billion | CN¥48.69 |
| #618 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of Zhejiang Tianyu Pharmaceutical Co Ltd (2017–2026)
Market capitalization of Zhejiang Tianyu Pharmaceutical Co Ltd from 2017 to today. Between 2017 and today, Zhejiang Tianyu Pharmaceutical Co Ltd's market cap moved from $760.42 Million to $ 1.03 Billion, with a yearly change of 6.15%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.03 Billion | -14.36% |
| 2025 | CN¥1.20 Billion | +41.66% |
| 2024 | CN¥848.33 Million | -23.06% |
| 2023 | CN¥1.10 Billion | -14.93% |
| 2022 | CN¥1.30 Billion | -47.07% |
| 2021 | CN¥2.45 Billion | -6.24% |
| 2020 | CN¥2.61 Billion | +87.37% |
| 2019 | CN¥1.39 Billion | +130.36% |
| 2018 | CN¥605.10 Million | -20.43% |
| 2017 | CN¥760.42 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of Zhejiang Tianyu Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.03 Billion USD |
| MoneyControl | $1.03 Billion USD |
| MarketWatch | $1.03 Billion USD |
| marketcap.company | $1.03 Billion USD |
| Reuters | $1.03 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Zhejiang Tianyu Pharmaceutical Co Ltd
Zhejiang Tianyu Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical intermediates and APIs in China and internationally. The company offers pharmaceutical intermediates and APIs of anti-hypertensive, anti-allergic, anticancer, anti-fungal, anti-epileptic, anti-asthmatic, hypoglycemic, hypolipidemic, and anticoagulant series. It also provides fine… Read more